Talc - Q14 2024 Update
Talc - Q4 2022 Update
The J&J Talc litigation is definitely a “mature” mass tort. There are approximately 34,00 cases filed in the MDL that was created and assigned to the United States district Court for the District of New Jersey on October 4, 2016. The United States Supreme Court declined to hear J&J’s plea for relief from the $2Billion Judgment taken against it. The St. Louis jury in July had initially awarded $550 million in compensatory damages and $4.14 billion in punitive damages for 22 women who used talc products and developed ovarian cancer. The state appeals court reduced the verdict to the $2Billion dollar figure and eliminated two of the Plaintiffs. More trials are set and expected to occur later this year and into 2022. J&J won a 2019 trial and one in 2017 but lost the aforementioned 2018 Missouri trial ($4.7 Billion Verdict), an August 2017 trial in California ($417 Million Verdict), a February 2016 trial in Missouri ($72 Million Verdict), and a May 2016 trial in Missouri ($55 Million Verdict). There will be more trials and more verdicts that J&J might win. That is not what is important, however. What is important is that the wins for the victims far outnumber the wins for J&J and the damages are significant. J&J has settled some cases and will be moving to settle more as it does not see this getting any better for them.
J&J is no stranger to litigation over its defective and dangerous products. J&J is faced with over 550 cases from its defective DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System, over 7,000 cases from its defective Pinnacle Acetabular Cup, over 13,500 related to its dangerous drug Xarelto, there is an 8 month old MDL over its dangerous drug Elmiron, a 5 year old MDL over its dangerous drug Invokana, and former MDLs regarding Levaquin and Transvaginal Mesh. Why would a huge American pharmaceutical and medical device company continue to make dangerous and defective products that bring the enormous numbers of lawsuits filed against it? It’s simple: J&J puts profits over people and sees the litigation as simply a cost of doing business as the profits it makes far exceeds the cost of litigation. Further, J&J is not alone in this corporate mentality.
J&J is no stranger to litigation over its defective and dangerous products. J&J is faced with over 550 cases from its defective DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System, over 7,000 cases from its defective Pinnacle Acetabular Cup, over 13,500 related to its dangerous drug Xarelto, there is an 8 month old MDL over its dangerous drug Elmiron, a 5 year old MDL over its dangerous drug Invokana, and former MDLs regarding Levaquin and Transvaginal Mesh. Why would a huge American pharmaceutical and medical device company continue to make dangerous and defective products that bring the enormous numbers of lawsuits filed against it? It’s simple: J&J puts profits over people and sees the litigation as simply a cost of doing business as the profits it makes far exceeds the cost of litigation. Further, J&J is not alone in this corporate mentality.
Talc - Q3 2022 Update
The J&J Talc litigation is definitely a “mature” mass tort. There are approximately 34,00 cases filed in the MDL that was created and assigned to the United States district Court for the District of New Jersey on October 4, 2016. The United States Supreme Court declined to hear J&J’s plea for relief from the $2 Billion Judgment taken against it. The St. Louis jury in July had initially awarded $550 million in compensatory damages and $4.14 billion in punitive damages for 22 women who used talc products and developed ovarian cancer. The state appeals court reduced the verdict to the $2Billion dollar figure and eliminated two of the Plaintiffs. More trials are set and expected to occur later this year and into 2022. J&J won a 2019 trial and one in 2017 but lost the aforementioned 2018 Missouri trial ($4.7 Billion Verdict), an August 2017 trial in California ($417 Million Verdict), a February 2016 trial in Missouri ($72 Million Verdict), and a May 2016 trial in Missouri ($55 Million Verdict). There will be more trials and more verdicts that J&J might win. That is not what is important, however. What is important is that the wins for the victims far outnumber the wins for J&J and the damages are significant. J&J has settled some cases and will be moving to settle more as it does not see this getting any better for them.
J&J is no stranger to litigation over its defective and dangerous products. J&J is faced with over 550 cases from its defective DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System, over 7,000 cases from its defective Pinnacle Acetabular Cup, over 13,500 related to its dangerous drug Xarelto, there is an 8 month old MDL over its dangerous drug Elmiron, a 5 year old MDL over its dangerous drug Invokana, and former MDLs regarding Levaquin and Transvaginal Mesh. Why would a huge American pharmaceutical and medical device company continue to make dangerous and defective products that bring the enormous numbers of lawsuits filed against it? It’s simple: J&J puts profits over people and sees the litigation as simply a cost of doing business as the profits it makes far exceeds the cost of litigation. Further, J&J is not alone in this corporate mentality.
J&J is no stranger to litigation over its defective and dangerous products. J&J is faced with over 550 cases from its defective DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System, over 7,000 cases from its defective Pinnacle Acetabular Cup, over 13,500 related to its dangerous drug Xarelto, there is an 8 month old MDL over its dangerous drug Elmiron, a 5 year old MDL over its dangerous drug Invokana, and former MDLs regarding Levaquin and Transvaginal Mesh. Why would a huge American pharmaceutical and medical device company continue to make dangerous and defective products that bring the enormous numbers of lawsuits filed against it? It’s simple: J&J puts profits over people and sees the litigation as simply a cost of doing business as the profits it makes far exceeds the cost of litigation. Further, J&J is not alone in this corporate mentality.
Q4 2021 Update
The J&J Talc litigation is definitely a “mature” mass tort. There are approximately 34,00 cases filed in the MDL that was created and assigned to the United States district Court for the District of New Jersey on October 4, 2016. The United States Supreme Court declined to hear J&J’s plea for relief from the $2Billion Judgment taken against it. The St. Louis jury in July had initially awarded $550 million in compensatory damages and $4.14 billion in punitive damages for 22 women who used talc products and developed ovarian cancer. The state appeals court reduced the verdict to the $2Billion dollar figure and eliminated two of the Plaintiffs. More trials are set and expected to occur later this year and into 2022. J&J won a 2019 trial and one in 2017 but lost the aforementioned 2018 Missouri trial ($4.7 Billion Verdict), an August 2017 trial in California ($417 Million Verdict), a February 2016 trial in Missouri ($72 Million Verdict), and a May 2016 trial in Missouri ($55 Million Verdict). There will be more trials and more verdicts that J&J might win. That is not what is important, however. What is important is that the wins for the victims far outnumber the wins for J&J and the damages are significant. J&J has settled some cases and will be moving to settle more as it does not see this getting any better for them.
J&J is no stranger to litigation over its defective and dangerous products. J&J is faced with over 550 cases from its defective DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System, over 7,000 cases from its defective Pinnacle Acetabular Cup, over 13,500 related to its dangerous drug Xarelto, there is an 8 month old MDL over its dangerous drug Elmiron, a 5 year old MDL over its dangerous drug Invokana, and former MDLs regarding Levaquin and Transvaginal Mesh. Why would a huge American pharmaceutical and medical device company continue to make dangerous and defective products that bring the enormous numbers of lawsuits filed against it? It’s simple: J&J puts profits over people and sees the litigation as simply a cost of doing business as the profits it makes far exceeds the cost of litigation. Further, J&J is not alone in this corporate mentality.
J&J is no stranger to litigation over its defective and dangerous products. J&J is faced with over 550 cases from its defective DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System, over 7,000 cases from its defective Pinnacle Acetabular Cup, over 13,500 related to its dangerous drug Xarelto, there is an 8 month old MDL over its dangerous drug Elmiron, a 5 year old MDL over its dangerous drug Invokana, and former MDLs regarding Levaquin and Transvaginal Mesh. Why would a huge American pharmaceutical and medical device company continue to make dangerous and defective products that bring the enormous numbers of lawsuits filed against it? It’s simple: J&J puts profits over people and sees the litigation as simply a cost of doing business as the profits it makes far exceeds the cost of litigation. Further, J&J is not alone in this corporate mentality.